Jefferies Global Healthcare Conference
Logotype for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals (VRTX) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Vertex Pharmaceuticals Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

2026-27 catalysts

  • Povetacicept’s IgAN PDUFA date is Nov. 30, 2026; phase II proof-of-concept data in DM1 are expected by year-end 2026.

  • AMPLITUDE phase III interim analysis of inaxaplin in APOL1-mediated kidney disease is expected in Q1 2027; positive results could support an accelerated-approval filing.

  • Povetacicept phase II proof-of-concept data in myasthenia gravis are expected in H1 2027; the study is fully enrolled.

  • Suzetrigine phase III diabetic peripheral neuropathy data are expected mid-2027; both 12-week studies are set to complete enrollment by end-2026.

Povetacicept clinical profile and opportunity

  • Interim IgAN results: 52% proteinuria reduction at week 36, >80% hematuria resolution and 42% of patients reaching KDIGO guidelines.

  • Proposed convenience profile: at-home, once-every-four-weeks auto-injector with a 0.46 mL dose and lower viscosity than peers.

  • Serious infections were 0.5% in both placebo and drug arms; management expects a class-consistent label without IgG monitoring and cited an on-track Nov. 30 PDUFA.

  • Two-year eGFR endpoint is important for Europe and Asian markets; estimated IgAN population is 1.5-1.6 million globally, versus 160,000 diagnosed in the U.S. and a similar population in Europe.

  • Commercial partners include Ono Pharma in Japan and surrounding countries and Zai Lab in China and surrounding countries; povetacicept is being developed for primary membranous nephropathy as well.

Inaxaplin and kidney pipeline

  • APOL1-related kidney decline was cited at 6-7 mL/min/year for patients with two variants, versus ~4 mL/min/year without them; initial phase II showed a 47.6% proteinuria reduction at week 13.

  • AMPLITUDE tests inaxaplin in patients with proteinuria of 0.7 g/g or higher; FDA discussions focus on eGFR slope, which must be met for accelerated approval.

  • AMPLIFIED showed a 44% proteinuria reduction at week 13 in the 0.3-0.7 g/g subgroup; AMPLITUDE interim data are expected early 2027.

  • U.S. APOL1 opportunity estimate: 150,000 patients with proteinuria, two APOL1 alleles and no comorbidities, plus another 100,000 with comorbidities such as type 2 diabetes.

  • Development plans include physician and community education, genotyping initiatives and a potential companion diagnostic; autosomal dominant polycystic kidney disease is also under evaluation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Vertex Pharmaceuticals